Verified

Investigator Initiated Studies

CSL

CSL is committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in the support for Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL products and the diseases they have been designed to treat. CSL also supports innovative clinical and basic science studies that address important medical and scientific questions related to our therapeutic Areas of Interest. Applicant proposals may request funding only, or funding and drug supply.

Investigator Commitments

Investigator‑Initiated Studies supported by CSL are conducted independently by the investigator or sponsoring institution. Investigators are responsible for study design, execution, and reporting, as well as obtaining all required ethical and regulatory approvals.
Investigators are expected to conduct studies in accordance with applicable laws and ethical standards, provide timely study updates and final results, appropriately acknowledge CSL support, and use any funding or product supplied solely for the approved research. Investigators are encouraged to disseminate study findings in a transparent and responsible manner, regardless of outcome.

Areas of Interest

Immunoglobulins

Hematology

Hereditary Angioedema (HAE)

IgA Nephropathy

The CSL IIS program is open to physicians, researchers and institutions interested in conducting their own research. We receive many requests for support and carefully evaluate each one with priority given to proposals that align with our research interests.

Disclaimer: Any application to participate in CSL’s IIS program, including any information shared in connection with such application, will be used by CSL for the sole purpose of evaluating the application, and will not be shared externally. To the extent that an application contains personal information about an individual, such information will be treated in accordance with CSL’s privacy policy, located at https://privacy.csl.com/.

Review Cycles

Application Cycle	Decision Communicated By
01 Jul – 21 Aug 2026	08 Oct 2026
01 Oct – 20 Nov 2026	21 Jan 2027
04 Jan – 19 Feb 2027	08 Apr 2027
01 Apr – 21 May 2027	08 Jul 2027

AI Based Application Success Predictor

The following ranking is a practical synthesis of CSL's published funding priorities and application requirements, not an official universal scoring rubric.

1

★★★★★

Strong alignment with CSL's therapeutic priorities

The project must address an area covered by the specific funding call, such as immunoglobulin therapy, hemophilia, hereditary angioedema, IgA nephropathy, acquired bleeding disorders or influenza vaccines.

CSL

2

★★★★★

Clear unmet medical need and patient benefit

Identify a meaningful clinical problem, such as delayed diagnosis, inadequate disease control, treatment burden or poor outcomes, and explain how the proposed work could address it.

3

★★★★★

Scientific quality and innovation

Use a well-supported rationale and a clear research question. For IIS proposals, CSL evaluates medical and scientific value alongside its current research priorities and available resources.

CSL

4

★★★★★

Methodological rigor and a complete protocol

For investigator-initiated studies, submit a developed study synopsis or draft protocol, appropriate endpoints, a defensible analysis plan, a detailed budget and the required investigator documentation. High-level concepts alone may be insufficient.

CSL

5

★★★★☆

Feasibility and access to resources

Demonstrate access to suitable patients, data, clinical sites, products or laboratory infrastructure, with realistic milestones and appropriate ethical and regulatory approvals.

6

★★★★☆

Relevant investigator expertise

Show that the principal investigator and collaborators have the skills needed to execute the work and report results responsibly. For fellowship awards, the applicant's research potential and career development are especially relevant.

7

★★★★☆

Clinically meaningful outcomes

Measure outcomes relevant to patients and clinical practice, including disease control, safety, quality of life, diagnostic accuracy, healthcare utilization or treatment effectiveness.

8

★★★★☆

Independence and transparency

For medical education and patient-organization grants, demonstrate that content, speakers, methods and activities remain independent of CSL's commercial influence. For IIS, the investigator or institution retains responsibility for study design, conduct and reporting.

CSL

9

★★★☆☆

Dissemination and sustainable impact

Explain how results will be reported, shared with clinicians or patients, and used to improve future research or clinical practice. Educational programs should specify their intended audience and measurable learning or patient outcomes.

10

★★★★☆

Eligibility, budget and application compliance

Use the correct regional portal, follow the submission cycle, provide the required documents and justify requested costs. Note that standard CSL grants and patient-organization grants are generally awarded to eligible organizations, not individuals.

Specialties

Hematology

Nephrology

Immunology

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: CSL

Sponsor Type: Corporate/Non-Profit

Address: 45 Poplar Road, Parkville, VIC 3052

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity